Name | Title | Contact Details |
---|
Next Level Solutions focuses exclusively on the technology needs of P&C insurance carriers. As a Systems Integrator partner with Duck Creek Technologies, we specialize in their full product suite and support projects of any scale. Next Levels Quality Assurance as a Service practice is equipped to test P&C systems to the highest standard and ensure a successful end-product, and our Shared Services offering provides a centralized, full-service IT and DevOps solution. Our passion and expertise mean a smarter solution for you.
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.
In 2011, KUIU was launched by founder Jason Hairston with the idea of bringing incredible technology and innovation to serious mountain hunters at fair prices. The goal was to fulfill this mission by doing business with uncompromised commitment to quality and consumer transparency. Utilizing a direct to consumer business model, KUIU has brought revolutionary equipment to the hunting industry based off of a technical layering system designed to keep you comfortable and dry in the most extreme hunting conditions. By eliminating the middleman and introducing unmatched technology at unbelievable pricing, KUIU is bringing to life its motto "Innovation Never Rests".
Welcome to The IN Group! The IN Group (TIG) beautifully brings together the magic of the group individual brands, Investigo, InX, Definia, Caraffi, Sigma Labs & BioTalent enabling us to design truly bespoke solutions. Our mission is simple - to unlock the power of people. We know that conventional recruitment cant always solve todays talent challenges, so we decided to break with convention and offer you SO much more with TIG. Meet our brands - Investigo – we recruit the talent you need - InX – we find the best leaders - Definia – we deliver digital programmes - Caraffi – we offer talent advisory & talent solutions (EVP/CVP/MSP/RPO) - Sigma Labs - we offer outstanding graduates amplified with exceptional training in the world of Tech - BioTalent - we offer life sciences recruitment with the means to nurture change-makers Unashamedly human talent solutions At the IN Group, were unashamedly human, were encourage to be our true self and we love what we do. We think youll feel this through the people you meet, the solutions we design and the results youll enjoy. We believe that when people rally behind an ambitious vision and a brilliant culture, it lights up every corner of your organisation. We believe in people, so they make change for better. Wed love to tell you more so come and say hello@wearetig.com and well tell you all about it!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.